List of Excipients in Branded Drug TYGACIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	TYGACIL	tigecycline	0008-4990	HYDROCHLORIC ACID
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	TYGACIL	tigecycline	0008-4990	LACTOSE MONOHYDRATE
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	TYGACIL	tigecycline	0008-4990	SODIUM HYDROXIDE
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	TYGACIL	tigecycline	0008-4994	HYDROCHLORIC ACID

Tygacil Excipient Strategy and Commercial Opportunities for Tigecycline Injection

Last updated: August 27, 2026

Tygacil is Pfizer’s intravenous tigecycline product, supplied as a 50 mg lyophilized powder for reconstitution. Its main commercial vulnerability is not active-ingredient differentiation. It is the injectable presentation, reconstitution burden, chemical stability, hospital handling requirements, broad generic availability, and FDA boxed warning on increased all-cause mortality. The strongest excipient opportunities are improved stability, ready-to-use delivery, reduced preparation steps, lower container waste, and formulations compatible with hospital infusion systems.

What is Tygacil and how is it formulated?

Tygacil contains tigecycline, a glycylcycline antibiotic derived from tetracycline chemistry. The FDA-approved product is administered intravenously for complicated skin and skin-structure infections and complicated intra-abdominal infections in adults and selected pediatric patients [1].

Attribute	Tygacil profile
Brand	Tygacil
Active ingredient	Tigecycline
Drug class	Glycylcycline antibacterial
Manufacturer	Pfizer
FDA application	NDA 21-821
Dosage form	Sterile lyophilized powder for injection
Strength	50 mg per vial
Route	Intravenous infusion
Standard adult dose	100 mg initial dose, followed by 50 mg every 12 hours
Reconstitution volume	Approximately 5.3 mL
Withdrawn volume	Approximately 5 mL
Approximate reconstituted concentration	10 mg/mL
Approved indications	Complicated skin and skin-structure infections; complicated intra-abdominal infections
Major regulatory limitation	Boxed warning for increased all-cause mortality
Commercial setting	Hospital and institutional use

The vial contains tigecycline as a lyophilized sterile product. The FDA label identifies lactose monohydrate as an inactive ingredient and permits reconstitution with 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer’s injection [1]. The reconstituted solution is yellow to orange and may darken over time without necessarily indicating loss of product quality, subject to labeled storage limits.

The formulation challenge is tigecycline’s aqueous instability. The molecule contains multiple functional groups that can undergo degradation under unsuitable pH, temperature, light, concentration, and diluent conditions. A commercial excipient strategy must therefore preserve potency while avoiding precipitation, excessive degradation products, infusion incompatibility, and unacceptable injection characteristics.

What excipients protect Tygacil?

The current Tygacil presentation uses a limited excipient system centered on lyophilization and pH adjustment. Public product information identifies lactose monohydrate and pH-adjusting agents associated with hydrochloric acid and sodium hydroxide [1,2].

Functional role of the excipient system

Excipient or component	Likely formulation function
Lactose monohydrate	Bulking agent and cake-forming excipient in the lyophilized vial
Hydrochloric acid	pH adjustment and control of solution chemistry
Sodium hydroxide	pH adjustment and neutralization during manufacture
Water for injection	Manufacturing solvent, removed during lyophilization
Sodium chloride, dextrose, or lactated Ringer’s solution	Permitted external diluents for reconstitution and infusion

The key intellectual-property value is likely to reside in the combination of tigecycline with controlled pH, lyophilization conditions, residual moisture limits, reconstitution parameters, and container-closure protection rather than in lactose alone.

A generic manufacturer can often reproduce the active product using a different excipient system if it demonstrates pharmaceutical equivalence, bioequivalence where required, sterility, stability, and acceptable labeling. That limits the ability to protect a simple "tigecycline plus lactose" formulation. More defensible claims would target a defined stability profile, a specific buffer system, a ready-to-use concentration, or a manufacturing process that produces a measurable product-quality advantage.

What formulation patents could protect tigecycline products?

The most commercially relevant patent categories are formulation, manufacturing, container-closure, and method-of-use claims.

Lyophilized powder patents

A lyophilized tigecycline product could be protected through claims covering:

• A specified tigecycline concentration before freezing
• A defined pH range
• Lactose or another carbohydrate bulking agent
• Controlled residual moisture
• Primary drying and secondary drying parameters
• Reconstitution time
• Limits on tigecycline epimerization or degradation products
• Stability after reconstitution
• Compatibility with selected infusion diluents

A formulation patent must provide more than a routine substitution of one bulking agent for another. The strongest patent position would link the excipient composition to a demonstrated technical effect, such as a longer in-use period, reduced degradation, or improved cake integrity.

Ready-to-use liquid formulations

A liquid tigecycline formulation could create a stronger commercial distinction than a second lyophilized vial. Patent claims could cover:

• Tigecycline concentration
• Buffer identity and concentration
• pH range
• Antioxidant or chelating-agent selection
• Oxygen control
• Light-protective packaging
• Refrigerated or room-temperature stability
• Polyolefin bag, glass vial, or cartridge presentation
• Compatibility with automated compounding systems

The technical barrier is higher because tigecycline’s stability in solution is more difficult to control than stability in a dry cake. A successful liquid product could reduce pharmacy labor, preparation errors, vial overfill, and discarded partial doses.

Container and device patents

Commercial protection may also come from:

• Dual-chamber bags containing diluent and drug
• Transfer devices for vial-to-bag reconstitution
• Closed-system transfer components
• Premixed infusion bags
• Single-dose containers with low residual volume
• Light-protective overwraps
• Automated pharmacy-compounding cartridges

These patents may be valuable even when the underlying drug formulation is no longer strongly protected. The commercial moat would come from workflow integration and hospital procurement contracts.

When did Tygacil lose market exclusivity?

Tygacil’s principal regulatory exclusivity periods ended years before the current generic market.

Milestone	Date or status
FDA approval	June 2005
Pediatric exclusivity extension	Added six months to applicable exclusivity periods
New chemical entity exclusivity	Expired in 2010, subject to the pediatric extension
Original compound and product patent protection	Expired before the current generic market period
Generic tigecycline availability	Established in the U.S. market
Current competitive position	Generic injectable competition

Tygacil is not a biologic, so biosimilar rules do not apply. Competitive products are abbreviated new drug application products, not biosimilars. The relevant FDA pathway is ANDA approval for tigecycline injection.

What is the Orange Book status of Tygacil?

The FDA Orange Book is the relevant source for listed patents and exclusivity associated with the Tygacil reference product [3]. The commercial importance of any historical Tygacil patents is now limited because the product has passed its NCE and original patent-protection period.

For a new tigecycline product, the key question is not whether Tygacil’s original composition claims remain enforceable. It is whether a later formulation, delivery, or manufacturing patent can create a distinct product position. A later patent would need to avoid routine formulation practice and withstand obviousness challenges based on known tetracycline chemistry, injectable excipients, and lyophilization techniques.

Which companies are challenging Tygacil with generic products?

Generic competition comes from manufacturers of tigecycline for injection approved through the ANDA pathway. The competitive field includes established injectable-generic companies and suppliers serving hospital group purchasing organizations.

The relevant competitive factors are:

1. FDA approval and supply reliability.
2. Compliance with sterile manufacturing requirements.
3. Contract pricing and shortage performance.
4. Vial configuration and overfill.
5. Reconstitution instructions.
6. Stability after reconstitution.
7. Ability to supply pediatric and adult hospital demand.
8. Presence on hospital formularies and GPO contracts.

A generic manufacturer does not need to reproduce the Tygacil excipient composition exactly. It must establish pharmaceutical equivalence and meet applicable quality and bioequivalence requirements. This makes excipient differentiation difficult unless the product offers an operational benefit.

What commercial opportunities exist for Tygacil excipients?

Ready-to-use tigecycline infusion

The clearest opportunity is a premixed, ready-to-administer product. Current vial preparation requires pharmacy personnel to reconstitute the powder, withdraw the required volume, dilute it into an infusion container, and manage unused material. A premixed product could reduce labor and preparation variability.

Potential customers include:

• Hospital pharmacies
• Emergency departments
• Operating rooms
• Long-term acute-care hospitals
• Home-infusion providers
• Specialty distributors
• Contract manufacturing organizations

The product would need validated stability across refrigerated and controlled-room-temperature conditions, compatibility with common infusion bags and tubing, and packaging that limits light and oxygen exposure.

Dual-chamber delivery

A dual-chamber bag could separate dry tigecycline from the infusion diluent until administration. This approach could preserve solid-state stability while eliminating manual vial reconstitution. It could also reduce contamination risk and improve nursing workflow.

The principal barriers are device cost, seal integrity, manufacturing complexity, and regulatory review of the combination product.

Improved lyophilized vials

A lower-cost opportunity is an optimized vial rather than a liquid or device product. Improvements could include:

• Faster reconstitution
• Reduced foaming
• More robust cake structure
• Lower residual moisture
• Smaller vial size
• Lower overfill
• Better visibility of the reconstituted solution
• Longer post-reconstitution stability

This strategy is easier to manufacture than a ready-to-use liquid but may produce less pricing power.

Excipient and packaging licensing

Excipient suppliers can commercialize value through licensing rather than direct drug sales. Relevant assets include:

• Stabilizing carbohydrate systems
• Low-peroxide excipients
• Specialized buffers
• Oxygen-scavenging packaging
• Light-protective polymers
• Lyophilization cycle development
• Sterile single-use transfer systems

The best licensing targets are generic manufacturers seeking differentiation or branded hospital-injectable companies seeking a line extension.

How strong is the patent estate for a new tigecycline formulation?

A new tigecycline formulation would have moderate patent potential but weak protection if based only on conventional excipient substitution.

Product concept	Patent potential	Commercial attractiveness	Main risk
Lactose-based lyophilized vial	Low to moderate	Moderate	Routine formulation and generic substitution
Alternative carbohydrate cake	Moderate	Moderate	Obviousness and limited clinical differentiation
Buffered ready-to-use liquid	Moderate to high	High	Chemical instability and shelf-life failure
Dual-chamber bag	High at device level	High	Device cost and combination-product review
Automated compounding cartridge	High at system level	Moderate to high	Hospital adoption and platform integration
Extended post-reconstitution stability	Moderate	High	Need for robust analytical proof
New method of use	Low unless clinically meaningful	Low to moderate	Existing safety warning and narrow indication

Method-of-use protection is constrained by the existing label and safety profile. New claims involving dosing, patient selection, or reduced toxicity would require credible clinical support. Excipient claims are more practical, but they should be tied to measurable performance characteristics.

What regulatory issues affect a new Tygacil formulation?

FDA review would focus on sterility assurance, particulate matter, extractables and leachables, degradation products, container closure, reconstitution, infusion compatibility, and stability. A liquid or device-based presentation may require more extensive chemistry, manufacturing, and controls work than a conventional generic vial.

The boxed warning for increased all-cause mortality remains a major commercial constraint [1]. A reformulated product does not remove the warning unless clinical evidence supports a regulatory change. Marketing should therefore focus on hospital workflow, preparation safety, supply reliability, and cost of administration rather than claims of superior clinical efficacy.

A new formulation may proceed through an ANDA only if it fits the applicable generic pathway. A materially different dosage form, delivery system, or clinical claim may require a different FDA submission strategy. Patent listings for a later product would depend on whether the formulation, method, or device meets Orange Book listing requirements.

What generic launch risks exist for a new tigecycline product?

The principal risks are:

• Low reimbursement and aggressive injectable-generic pricing
• Limited differentiation from existing tigecycline vials
• Hospital reluctance to pay a premium for convenience
• Sterile manufacturing failures
• Supply interruptions involving glass vials, stoppers, or infusion bags
• Degradation during storage or transport
• Incompatibility with commonly used diluents
• Limited treatment volume because of the boxed warning
• Patent challenges against formulation claims
• Procurement concentration through GPOs

A premium product is more likely to succeed if it produces a documented reduction in pharmacy preparation time, medication waste, or administration errors. A small excipient change without workflow impact is unlikely to command durable pricing.

How does Tygacil compare with competing hospital antibiotics?

Tigecycline competes with broad-spectrum hospital antibiotics including meropenem, ertapenem, piperacillin-tazobactam, vancomycin combinations, and newer agents directed at resistant Gram-negative organisms. These products often have stronger formulary positions because of broader indication utility, more established dosing workflows, or fewer safety limitations.

Tigecycline’s formulation opportunity is therefore operational rather than purely therapeutic. A ready-to-use product could compete for hospital convenience even where the active ingredient remains clinically restricted. The product would need a clear total-cost benefit, not merely a different excipient list.

Key Takeaways

• Tygacil is a 50 mg lyophilized tigecycline injection supplied for hospital intravenous use.
• Lactose monohydrate and pH adjustment are central elements of the publicly described formulation.
• Original NCE and patent exclusivity have expired; generic tigecycline competition is established.
• Tigecycline is a small-molecule drug, so biosimilar risk does not apply.
• The strongest commercial opportunity is a ready-to-use liquid, dual-chamber bag, or workflow-integrated delivery system.
• The strongest patent claims would link excipients and packaging to improved stability, extended in-use time, reduced degradation, or device performance.
• A reformulation does not remove Tygacil’s FDA boxed warning.
• Hospital labor savings, reduced waste, and supply reliability are more credible value drivers than clinical differentiation.

FAQs

Can lactose be replaced in a generic tigecycline formulation?

Yes. A generic manufacturer may use a different excipient system if the product meets FDA requirements for pharmaceutical equivalence, quality, sterility, stability, and labeling.

Is a premixed tigecycline infusion commercially feasible?

Yes, but the product must overcome tigecycline’s solution stability, packaging, light exposure, and degradation-control challenges. Its value would come from reduced pharmacy preparation and administration burden.

Does tigecycline have biosimilar competition?

No. Tigecycline is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways rather than the biosimilar pathway.

Can a new excipient create Orange Book-listed protection for tigecycline?

Potentially. The formulation must satisfy patentability standards, and the patent must claim a qualifying drug product or method of use. A routine excipient substitution is vulnerable to invalidity challenges.

What is the best licensing target in the Tygacil market?

A validated stabilization and delivery platform that enables ready-to-use tigecycline with commercially meaningful shelf life is the strongest target. A conventional lyophilized excipient package has less licensing value unless it provides a measurable manufacturing or stability advantage.

References

1. U.S. Food and Drug Administration. (2020). Tygacil (tigecycline) prescribing information. Pfizer Laboratories. https://labeling.pfizer.com/ShowLabeling.aspx?id=491

2. National Library of Medicine. (n.d.). Tygacil- tigecycline injection, powder, lyophilized, for solution. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm